Medicom (Metformin Hydrochloride Tablets) is a hypoglycemic drug. Medikom (Metformin Hydrochloride Tablets) can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes mellitus, and HbAlc can be decreased by 1%-2%.The hypoglycemic effect of Medikom (Metformin Hydrochloride Tablets) may be:

1. Increase the sensitivity of peripheral tissues to insulin, and increase the insulin-mediated glucose utilization.

2. Increase glucose utilization by non-insulin-dependent tissues, such as brain, blood cells, renal medulla, intestine, and skin.

3. Inhibits hepatic glycogen isomerization and decreases hepatic glucose output.

4. Inhibits glucose uptake by intestinal wall cells.

5. Inhibit cholesterol biosynthesis and storage, reduce blood triglyceride and total cholesterol levels. Unlike the action of insulin, Medikom (Metformin Hydrochloride Tablets) does not promote fat synthesis, has no significant hypoglycemic effect on normal people, and generally does not cause hypoglycemia when applied alone in type II diabetes mellitus.